Abbott launches Crohn's disease podcasts

Share this article:

Abbott has launched a series of podcasts, or “Crohn's Casts,” offering information and insights into Crohn's disease.

The podcasts – which feature clinical information from practicing health professionals and testimony from Crohn's sufferers – are located on an unbranded website, explained Michelle Johnson, manager, public affairs, at Abbott, though patients have “opportunities to get additional information,” she said. 

“This is the first time [Abbott] has used podcasts to create awareness for a disease,” said Johnson, adding that the company will “evaluate results when the series is finished, and assess the feedback.”

Abbott markets Humira (adalimumab), a tumor necrosis factor blocker, for the treatment of Crohn's disease. A link to the Crohn's Casts website can be found on the product page for Humira or click here.

The Crohn's disease podcasts are a valuable source of information for both patients and physicians, since the general public isn't as familiar with the disease, noted Johnson.

“People with Crohn's disease suffer from symptoms they don't necessarily want to talk about,” like digestive difficulties, said Johnson. Crohn's disease is most often diagnosed in patients between the ages of 15 and 35 – another reason podcasts make sense, according to Johnson. “People are going online, and they are looking for trusted resources,” she said.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?